CTP (Computed Tomography Perfusion) Imaging of Lung Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non Small Cell Lung Cancer
- Sponsor
- University of California, Davis
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Yield of conducting CTP studies
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Investigators hope to learn more about how to use computed tomography (CT) scans to measure blood flow in lung tumors and how it may change in response to treatment. This measurement technique is called computed tomography perfusion (CTP). CT scanners use X-rays to produce 3-dimensional images of the body.
Currently, doctors determine the response to treatment by measuring the size of the tumor. Investigators are trying to find out if measuring the blood flow in the tumor is equal to or better than measuring the size of the tumor.
Detailed Description
This is an experimental study of CT perfusion (CTP) imaging in subjects with non-small cell lung cancer. The objectives of this study are to demonstrate the feasibility of CT blood flow measurements in lung cancer, to develop a foundation for the use of CT blood flow measurements in lung cancer to assess the response to treatment, and to develop an optimized CTP imaging protocol for evaluating blood flow in solid body tumors. In this study, tumor blood flow will be evaluated at baseline and follow-up routine CT examinations of patients with non-small cell lung cancer, and the response of tumor blood flow will be recorded as a secondary endpoint. This research study will entail two study visits - one required and one optional - which will coincide with regularly scheduled standard of care CT scans.
Investigators
Eligibility Criteria
Inclusion Criteria
- •adult patients with non small cell lung cancer who receive, or are considered for, systemic therapy
Exclusion Criteria
- •renal failure pregnancy known contrast allergy
Outcomes
Primary Outcomes
Yield of conducting CTP studies
Time Frame: 2 years
Yield is determined as the percentage of assessable CTP studies, relative to all performed studies
Secondary Outcomes
- Variability of CTP measurements(2 years)
- Magnitude of treatment induced changes in tumor blood flow(2 years)